Red cell N5-methyltetrahydrofolate concentrations and C677T methylenetetrahydrofolate reductase genotype in patients with stroke

Aims: To investigate the relation between total red cell folate, red cell N5-methyltetrahydrofolate (N5MTHF) concentrations, and N5N10-methylenetetrahydrofolate reductase (MTHFR) genotypes in stroke. Methods: The study comprised 120 consecutive patients presenting to hospital with acute stroke. Multivitamin supplement use was recorded. Serum and red cell folate were measured by microbiological assays using Lactobacillus casei and Enterococcus faecalis, and by the DPC-BioMediq Immulite™ 2000 analyser. Total plasma homocysteine (tHcy), serum cobalamin, and serum vitamin B6 were measured and the C677T MTHFR genotype determined. Results: There were no significant differences in blood tHcy or vitamin concentrations according to MTHFR genotype in the overall patient cohort. However, when patients taking vitamins were excluded, total red cell folate and red cell N5MTHF were significantly lower in patients with the TT genotype compared with CT or CC genotypes. In the overall cohort, irrespective of genotype, red cell folate was significantly lower when assayed microbiologically than with the Immulite assay. This discrepancy remained after exclusion of patients taking vitamins. Conclusion: Total red cell folate and red cell N5MTHF are significantly lower in stroke patients with the TT compared with the CT and TT MTHFR genotypes, particularly those not taking vitamin supplements. Microbiological assays that measure biologically active folates provide substantially lower estimates of folate than the Immulite™ assay. Because folate is a key determinant of blood homocysteine values, these findings may impact on the interpretation of the strength and independence of the association between raised blood concentrations of homocysteine and atherothrombosis risk reported in most epidemiological studies.

[1]  Patients have no appetite for HSV-2 screening , 2003 .

[2]  D. Wald,et al.  Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis , 2002, BMJ : British Medical Journal.

[3]  Petra Verhoef,et al.  MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.

[4]  L. Kluijtmans,et al.  Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk. , 2001, European heart journal.

[5]  H. Watkins,et al.  Evolution of genetic analysis strategies in coronary heart disease: a case of unnatural selection? , 2001, European Heart Journal.

[6]  P. Finglas,et al.  Erythrocyte folate analysis: saponin added during lysis of whole blood can increase apparent folate concentrations, depending on hemolysate pH. , 2000, Clinical chemistry.

[7]  G. Hankey,et al.  Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. , 2000, Stroke.

[8]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[9]  G. Hankey,et al.  Homocysteine and vascular disease , 1999, The Lancet.

[10]  T. Imaizumi,et al.  Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. , 1999, Clinical science.

[11]  G. Assmann,et al.  Association of Red-blood Methylfolate but not Plasma Folate with C677T MTHFR Polymorphism in Venous Thromboembolic Disease , 1998, Thrombosis and Haemostasis.

[12]  J. Finkelstein,et al.  The metabolism of homocysteine: pathways and regulation , 1998, European Journal of Pediatrics.

[13]  H. Markus,et al.  A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. , 1997, Stroke.

[14]  S. Daly,et al.  Thermolabile variant of 5, 10-methylenetetrahydrofolate reductaseassociated with low red-cell folates: implications for folate intake recommendations , 1997, The Lancet.

[15]  S. S. Kang,et al.  Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. , 1996, Atherosclerosis.

[16]  M. den Heyer,et al.  Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida , 1995, The Lancet.

[17]  R. Davis,et al.  An automated method for the microbiological assay of serum pyridoxal , 1973, Journal of clinical pathology.

[18]  R. Davis,et al.  An automated method for the measurement of folate activity , 1970, Journal of clinical pathology.

[19]  J. Mills,et al.  Whole-blood folate values in subjects with different methylenetetrahydrofolate reductase genotypes: differences between the radioassay and microbiological assays. , 1998, Clinical chemistry.

[20]  K. Brownbill,et al.  When is an indole not an indole? , 1998, Clinical chemistry.

[21]  P. Frosst,et al.  Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. , 1996, American journal of human genetics.

[22]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[23]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[24]  H. Blom,et al.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. , 1995, American journal of human genetics.

[25]  K. S. Lau.  Methods in Haematology, Vol. 10, The Cobalamins, Charles A. Hall (Ed.). Churchill Livingstone, Edinburgh, London, Melbourne and New York (1983), 219, ISBN 0 443 02769 2. $56.00 , 1985 .

[26]  E. V. Cox.  The megaloblastic anaemias. , 1965, Nursing times.